🔥🐔 BizChicken 🐔🔥

Companies Similar to Amgen Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

AnaptysBio, Inc.

AnaptysBio, Inc. logo
Market Cap: Medium
Employees: Low

Imsidolimab, Rosnilimab, ANB032

Anaptys Bio, Inc. is a clinical stage biotechnology company focused on developing therapeutic product candidates for inflammation and immuno-oncology indications. Their products target dermatological inflammatory diseases and other human inflammatory conditions.

Tags: antibody development, biotechnology, immuno-oncology, inflammation, therapeutics

Symbol: ANAB

Recent Price: $13.22

Industry: Biotechnology

CEO: Mr. Daniel R. Faga

Sector: Healthcare

Employees: 117

Address: 10770 Wateridge Circle, San Diego, CA 92121-5801

Phone: 858 362 6295

Last updated: 2024-12-31

Amgen Inc.

Amgen Inc. logo
Market Cap: Highest
Employees: Highest

Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, KYPROLIS, Repatha, Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide, focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

Tags: biotechnology, bone health, cardiovascular, healthcare, inflammation, neuroscience, oncology, pharmaceuticals, therapeutics

Symbol: AMGN

Recent Price: $259.30

Industry: Drug Manufacturers - General

CEO: Mr. Robert A. Bradway

Sector: Healthcare

Employees: 26700

Address: One Amgen Center Drive, Thousand Oaks, CA 91320-1799

Phone: 805 447 1000

Leadership

  • Robert A. Bradway, Chairman and Chief Executive Officer
  • James Bradner, Executive Vice President, Research and Development, and Chief Scientific Officer
  • Sean Bruich, Senior Vice President Artificial Intelligence and Data
  • Paul Burton, Senior Vice President and Chief Medical Officer
  • Raymond Deshaies, Senior Vice President, Global Research
  • Jackie Elbonne, Senior Vice President, Quality and Chief Quality Officer
  • Murdo Gordon, Executive Vice President, Global Commercial Operations
  • Jonathan Graham, Executive Vice President and General Counsel and Secretary
  • Peter Griffith, Executive Vice President and Chief Financial Officer
  • Nancy Grygiel, Senior Vice President, Worldwide Compliance & Business Ethics and Chief Compliance Officer
  • Narimon Honarpour, Senior Vice President, Global Development
  • Vikram Karnani, Executive Vice President, and President, Global Commercial Operations and Medical Affairs (Rare Disease)
  • My Linh Kha, Senior Vice President and General Manager, Japan Asia-Pacific
  • Rachna Khosla, Senior Vice President, Business Development
  • Gilles Marrache, Senior Vice President, Regional General Manager
  • Derek Miller, Senior Vice President, Human Resources
  • Jerry Murry, Senior Vice President, Process Development
  • Kave Niksefat, Senior Vice President, Global Marketing and Access
  • Arleen Paulino, Senior Vice President, Manufacturing
  • Annalisa Pizzarello, Senior Vice President, Results Delivery Office
  • Greg Portner, Senior Vice President, Global Government Affairs and Policy
  • Anton Rabushka, Senior Vice President, Finance
  • Emily Razaqi, Senior Vice President, Obesity and Related Conditions
  • David M. Reese, Executive Vice President and Chief Technology Officer
  • Esteban Santos, Executive Vice President, Operations
  • Darryl Sleep, Senior Vice President, Global Medical
  • Jean-Charles Soria, Senior Vice President, Research and Development
  • Susan Sweeney, Executive Vice President, Obesity and Related Conditions
  • Mark J. Taisey, Senior Vice President, Global Regulatory Affairs and Strategy
  • Susie Tappouni, Head of Corporate Affairs
  • Ian Thompson, Senior Vice President, U.S. Business Operations
  • Brenda Torres, Senior Vice President, Global Supply Chain
  • Alper Üreten, Vice President, Commercialization and Program Management
  • Wanda M. Austin, Retired President and Chief Executive Officer, The Aerospace Corporation
  • Michael V. Drake, President, University of California
  • Brian J. Druker, Physician-Scientist and Professor of Medicine, Oregon Health & Science University (OHSU), Director of the OHSU Knight Cancer Institute and JELD-WEN Chair of Leukemia Research, and Associate Dean for Oncology, OHSU School of Medicine
  • Robert A. Eckert, Lead Independent Director, Chairman Emeritus, Mattel, Inc.
  • Greg C. Garland, Former Executive Chairman and Former Chairman and Chief Executive Officer, Phillips 66
  • Charles M. Holley, Jr., Former Executive Vice President and Chief Financial Officer of Wal-Mart Stores, Inc.
  • S. Omar Ishrak, Former Executive Chairman and Chairman of the Board of Directors, Medtronic plc
  • Tyler Jacks, David H. Koch Professor of Biology, Massachusetts Institute of Technology and Founding Director of the David H. Koch Institute for Integrative Cancer Research
  • Mary E. Klotman, Executive Vice President for Health Affairs of Duke University, Dean of the Duke University School of Medicine, and Chief Academic Officer of Duke Health
  • Ellen J. Kullman, Executive Chair of the Board and Former President and Chief Executive Officer of Carbon, Inc.
  • Amy E. Miles, Former Chair of the Board and Chief Executive Officer, Regal Entertainment Group, Inc.

Last updated: 2024-12-31

Gilead Sciences, Inc.

Gilead Sciences, Inc. logo
Market Cap: Highest
Employees: Highest

Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.

Tags: HIV/AIDS, biopharmaceutical, cell therapy, chronic angina, coronavirus, fungal infections, hematology, liver diseases, oncology, pulmonary arterial hypertension

Symbol: GILD

Recent Price: $92.01

Industry: Drug Manufacturers - General

CEO: Mr. Daniel P. O'Day

Sector: Healthcare

Employees: 18000

Address: 333 Lakeside Drive, Foster City, CA 94404

Phone: 650 574 3000

Leadership

  • Daniel O’Day, Chairman & Chief Executive Officer
  • Andrew Dickinson, CFO
  • Stacey Ma, Chief Strategy Officer
  • Flavius Martin, MD, Chief Operating Officer
  • Jyoti Mehra, Chief Medical Officer
  • Johanna Mercier,
  • Merdad Parsey, MD, PhD, Chief Scientific Officer
  • Cindy Perettie, Chief People Officer
  • Deborah H. Telman,
  • Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
  • Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
  • Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
  • Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
  • Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
  • Harish Manwani, Senior Operating Partner, Blackstone Inc.
  • Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
  • Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
  • John Smith, CEO
  • Linda White, Chief Marketing Officer
  • Robert Brown, Chief Operating Officer
  • Michael Davis, President
  • John Doe, CEO
  • Jane Smith, CFO
  • Emily Johnson, CTO
  • Michael Brown, Director of Operations
  • Linda Davis, Director
  • Alice Johnson, CTO
  • Susan Martinez, Chairman
  • Jane Doe, CFO
  • James Davis, Chairman
  • Patricia Miller, President

Last updated: 2024-12-31

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

ENHANZE drug delivery technology

Halozyme Therapeutics, Inc. is a biopharma technology platform company specializing in enabling subcutaneous delivery of biologics using its patented ENHANZE technology. The company operates in the United States and internationally, offering products such as Hylenex recombinant and developing treatments for various medical conditions including lymphomas and immunodeficiency disorders.

Tags: ENHANZE, biologics, biopharma, drug delivery, technology, therapeutics

Symbol: HALO

Recent Price: $47.99

Industry: Biotechnology

CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

Sector: Healthcare

Employees: 373

Address: 11388 Sorrento Valley Road, San Diego, CA 92121

Phone: 858 794 8889

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten Bönnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Highest

Emverm, Rytary, Unithroid

Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products across various dosage forms and therapeutic areas, operating through Generics, Specialty, and Av KARE segments.

Tags: Generics, Healthcare, Pharmaceuticals, Specialty, Therapeutics

Symbol: AMRX

Recent Price: $7.83

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Chirag K. Patel

Sector: Healthcare

Employees: 7850

Address: 400 Crossing Boulevard, Bridgewater, NJ 08807

Phone: 908 947 3120

Leadership

  • Chirag Patel, President and Co-Chief Executive Officer
  • Chintu Patel, Co-Chief Executive Officer
  • Tasos Konidaris, Executive Vice President, Chief Financial Officer
  • Nikita Shah, Executive Vice President, Chief Human Resources Officer
  • Jason B. Daly, Esq., Senior Vice President, Chief Legal Officer & Corporate Secretary
  • Gregory Sgammato, Senior Vice President, Corporate Development
  • Andrew S. Boyer, Executive Vice President, Chief Commercial Officer – Generics
  • Joe Renda, Senior Vice President, Chief Commercial Officer - Specialty
  • Shyamakant Giri, President, India Business & Emerging Markets
  • Sanjay Kumar Jain, PhD, Chief Quality Officer
  • Srinivas Kone, PhD, Senior Vice President, Chief Scientific Officer – Generics
  • Richard D’Souza, PhD, Senior Vice President, Specialty R&D
  • Maryll W. Toufanian, Senior Vice President, Regulatory Strategy and Government Affairs
  • Pranav Mehta, Senior Vice President, Strategic Sourcing & Supply Management
  • Sandeep R. Raktate, President, Operations – India & Ireland

Last updated: 2024-12-31

Agenus Inc.

Agenus Inc. logo
Market Cap: Low
Employees: Medium

Retrocyte Display

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.

Tags: antibody expression, cancer treatment, clinical trials, immuno-oncology, vaccine development

Symbol: AGEN

Recent Price: $2.69

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 389

Address: 3 Forbes Road, Lexington, MA 02421-7305

Phone: 781 674 4400

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Omega Therapeutics, Inc.

Omega Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

OMEGA Epigenomic Programming platform

Omega Therapeutics, Inc. is a development-stage biopharmaceutical company leveraging its OMEGA Epigenomic Programming platform to utilize the power of epigenetics for therapeutic interventions across various diseases.

Tags: biopharmaceutical, chronic liver diseases, corneal regeneration, epigenetics, gene control, idiopathic pulmonary fibrosis

Symbol: OMGA

Recent Price: $0.80

Industry: Biotechnology

CEO: Mr. Mahesh Karande

Sector: Healthcare

Employees: 93

Address: 20 Acorn Park Drive, Cambridge, MA 02140

Phone: 617 949 4360

Leadership

  • Mahesh Karande, President & Chief Executive Officer
  • Kaan Certel, Ph.D., Chief Business Officer
  • Jennifer Nelson, Ph.D., Senior Vice President, Research
  • Tony Mullin, Chief People Officer
  • Barbara Chan, Senior Vice President, Finance and Chief Accounting Officer
  • Lisamarie Fahy, Senior Vice President, Clinical Development Operations
  • Joe Newman, Ph.D., Senior Vice President, Early Discovery
  • Jeff Atkinson, Ph.D., Vice President, Technical Operations
  • Eva Stroynowski, Senior Vice President, Investor Relations and Corporate Affairs

Last updated: 2024-12-31

Puma Biotechnology, Inc.

Puma Biotechnology, Inc. logo
Market Cap: Low
Employees: Low

PB272 (neratinib, oral)

Puma Biotechnology, Inc. focuses on the development and commercialization of products to enhance cancer care, with drug candidates including PB272 neratinib for various stages and types of cancer, and has various license agreements for its product distribution.

Tags: HER2-positive, biopharmaceutical, breast cancer, cancer care, drug development, solid tumors

Symbol: PBYI

Recent Price: $3.13

Industry: Biotechnology

CEO: Mr. Alan H. Auerbach

Sector: Healthcare

Employees: 185

Address: 10880 Wilshire Boulevard, Los Angeles, CA 90024

Phone: 424 248 6500

Leadership

  • Alan H. Auerbach, President and Chairman of the Board
  • Maximo F. Nougues, Chief Financial Officer
  • Jeff J. Ludwig, Chief Commercial Officer
  • Douglas Hunt, B.Sc (Hons), Senior Vice President, Regulatory Affairs, Pharmacovigilance, Medical Affairs and Law

Last updated: 2024-12-31

AbbVie Inc.

AbbVie Inc. logo
Market Cap: Highest
Employees: Highest

HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, MAVYRET, CREON, Synthroid, Linzess/Constella, Lupron

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a range of therapies including HUMIRA for autoimmune diseases and MAVYRET for HCV infection.

Tags: autoimmune diseases, biotechnology, gastroenterology, healthcare, oncology, pharmaceuticals

Symbol: ABBV

Recent Price: $176.20

Industry: Drug Manufacturers - General

CEO: Mr. Robert A. Michael

Sector: Healthcare

Employees: 50000

Address: 1 North Waukegan Road, North Chicago, IL 60064-6400

Phone: 847 932 7900

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. logo
Market Cap: High
Employees: Medium

AG10, BBP-265, BBP-831, BBP-631, Encaleret

Bridge Bio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases, with a pipeline of 30 programs including candidates like AG10, BBP-265, and others in various stages of clinical trials.

Tags: biopharmaceuticals, clinical trials, drug development, genetic diseases

Symbol: BBIO

Recent Price: $27.32

Industry: Biotechnology

CEO: Dr. Neil Kumar Ph.D.

Sector: Healthcare

Employees: 550

Address: 421 Kipling Street, Palo Alto, CA 94301

Phone: 650 391 9740

Last updated: 2024-12-31

Nektar Therapeutics

Nektar Therapeutics logo
Market Cap: Low
Employees: Low

Bempegaldesleukin

Nektar Therapeutics is a biopharmaceutical company focused on developing medicines for unmet medical needs. Their products include Bempegaldesleukin, an IL-2 pathway agonist in clinical trials for various cancers and COVID-19, and NKTR-358, a cytokine Treg stimulant for autoimmune diseases.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, medicines, oncology

Symbol: NKTR

Recent Price: $0.94

Industry: Biotechnology

CEO: Mr. Howard W. Robin

Sector: Healthcare

Employees: 137

Address: 455 Mission Bay Boulevard South, San Francisco, CA 94158

Phone: 415 482 5300

Leadership

  • Howard W. Robin, President & Chief Executive Officer
  • Robert Bacci, Senior Vice President, HR and Facilities Operations
  • Sandra Gardiner, Chief Financial Officer
  • Jennifer Ruddock, Chief Business Officer
  • Mary Tagliaferri, M.D., Chief Medical Officer
  • Mark A. Wilson, Chief Legal Officer
  • Jonathan Zalevsky, Ph.D., Chief Research & Development Officer

Last updated: 2024-12-31